Fentanyl

Fentanyl
Product Description

This API is part of the FCC product portfolio and is available for selected markets only

Aspen Healthcare. We Care

  • NL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)
Specifications
  • CAS Registry Number
    437-38-7
  • Supplied from
    South Africa

Aspen Healthcare. We Care

  • NL
  • 2015
    On CPHI since
  • 4
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Generic APIs producer
Pharmaceutical Company (generic finished products)

More Products from Aspen Healthcare. We Care (58)

  • Segesterone acetate

    Product Segesterone acetate

    Under development - samples are available
  • Sugammadex

    Product Sugammadex

    Commercially available
  • Morphine Sulfate

    Product Morphine Sulfate

    This API is part of the FCC product portfolio and is available for selected markets only
  • Morphine Tartrate

    Product Morphine Tartrate

    This API is part of the FCC product portfolio and is available for selected markets only
  • Morphine Hydrochloride

    Product Morphine Hydrochloride

    This API is part of the FCC product portfolio and is available for selected markets only 
  • Fentanyl citrate

    Product Fentanyl citrate

    This API is part of the FCC product portfolio and is available for selected markets only 
  • Codeine Hydrochloride

    Product Codeine Hydrochloride

    This API is part of the FCC product portfolio and is available for selected markets only
  • Chorionic Gonadotrophin (HCG)

    Product Chorionic Gonadotrophin (HCG)

    Aspen Oss B.V offers a wide range of high quality APIs. Chorionic Gonadotrophin is part of our biochemical portfolio. Key characteristics of Chorionic Gonadotrophin are: • Dedicated facilities and equipment for extraction and purification • Full quality oversight, control and traceability through our exte...
  • Heparin sodium

    Product Heparin sodium

    Aspen Oss B.V offers a wide range of products which includes heparin sodium. Contact us for more information.
  • Desmopressin

    Product Desmopressin

    Desmopressin is part of our peptide portfolio. All our APIs are produced routinely and on commercial scale according to cGMP.Aspen Oss has 50 years of peptide experience. We have a batch to batch reproducibility combined with high yield and purify profiles.
  • Gonadorelin acetate (LH-RH)

    Product Gonadorelin acetate (LH-RH)

    Gonadorelin acetate is part of our peptide portfolio. All our APIs are produced routinely and on commercial scale according to cGMP.

    Aspen Oss has 50 years of peptide experience. We have a batch to batch reproducibility combined with high yield and purify profiles.

  • Leuprorelin (Leuprolide)

    Product Leuprorelin (Leuprolide)

    Leuprorelin is part of our peptide portfolio. All our APIs are produced routinely and on commercial scale according to cGMP.

    Aspen Oss has 50 years of peptide experience. We have a batch to batch reproducibility combined with high yield and purify profiles.

Aspen Healthcare. We Care resources (3)

  • Sponsored Content Aspen API’s Green answer to peptide synthesis

    Our Green Continuous Liquid Phase Peptide Synthesis (GC-LPPS) combines the advantages of the classical solution-phase synthesis with the solid-phase approach. 
  • Brochure Aspen. Healthcare. We Care.

    Aspen is a global specialty and branded pharmaceutical company committed to promoting access to medicines and improving the health of patients across the world through our high quality, affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability.
  • News CPHI Trend Report - Sustainability in Pharma

    While in the past, much of the discussion around sustainability in the pharmaceutical industry rightly focused on efforts to minimize the environmental impact of drug production, the needle has now shifted. There are signs that companies not only understand that it represents one of the world’s biggest challenges moving forward, but also that they are starting to incorporate sustainability practices into a much broader suite of operations.